SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Stressgen (VSE: SSB)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: William Marsh who wrote (99)10/21/1999 5:19:00 PM
From: Heat Shock  Read Replies (1) of 236
 
William, I agree with your remarks.

One nice thing about the Genzyme acquisition of Cell Genesys is that GZMO will acquire new gene delivery vectors. This raises the possibility, however faint, that the back burner stress protein gene therapy could be tried with some of these new vectors. This would pertain if the stress protein gene therapy "equivocal results" were due to the vector. The CELG web site says they have retroviral vectors, adenoviral vectors, adeno-associated viral vectors and lentiviral vectors.

Heat
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News